Join our daily newsletter At The Bell to receive exclusive market insights
The ASX200 is down nearly .7 of a per cent – almost on par with futures’ predictions – with most sectors, apart from energy, in the red.
The Australian Bureau of Statistics released data showing that imported goods rose by 4.8 per cent in February, while exports fell by 2.2% during the same period.
Today we’ve shone the spotlight on Barton Gold, Dreadnought Resources and OncoSil Medical.
https://themarketonline.com.au/asx-bgd/ shot up nearly 6 per cent despite raising $3 million through a strategic placement – priced at 24 cents and is now seeking to top this up with a share purchase plan (SPP) to raise an additional $1 million to support its exploration initiatives.
Barton is seeking to pin down what it defines as ‘district scale structures’ at the Tunkillia gold project in South Australia, which holds a mineral resource estimate of 1.5 million ounces, while also expediting exploration at nearby Tarcoola.
BGD has been trading above the raise price at 27 cents.
Dreadnought Resources (ASX:DRE) has kicked off its first focused drilling campaign on four high priority gold targets at its Central Yilgarn project in Western Australia.
The exploration work will include 15 holes and 1,800 metres of drilling, with results to be reported in June.
With gold prices spiking around the USD$2300 an ounce, the company believes it is well positioned to be defining the project’s mineralisation at this point in time.
DRE has been trading at 1.8 cents.
OncoSil Medical (ASX:OSL) – on a mission to combat pancreatic cancer – is up nearly 30 per cent – after dosing the first two patients in Austria with its OncoSilTM device.
The company also confirmed its penetration of key European countries, notably Spain, Italy, Greece, and now Austria.
This list is expected to expand further with other countries, including the UK, Portugal and Germany, having already commenced training on the usage of the device.
OSL has been trading at 0.7 cents.
